Jim Cramer highlights Moderna's shift beyond Covid vaccines with a growing pipeline in cancer treatments and new vaccines, signaling a promising future. Despite shares being below their pandemic peak, the stock has surged nearly 150% this year, driven by optimism around Moderna's oncology programs and upcoming FDA decisions on new vaccines. Investors are advised to be patient and consider buying on dips as these developments could fuel long-term growth. Key milestones include late-stage cancer trials and potential flu vaccine approvals, marking a strategic pivot for Moderna's growth beyond Covid.

More News (MRNA)

Wall Street rises as Fed rate cut hopes grow despite weak jobs data

Wall Street ended the holiday-shortened week higher, driven by optimism over a potential Federal Reserve interest rate cut by year-end despite weaker-than-expected June jobs data. Technology stocks rebounded early in the week amid easing U.S.-Iran te...

Market News

Bullish

2 days ago